Published January 11, 2026
A new clinical trial is examining the potential of extracorporeal shockwave therapy in treating Peyronie’s disease, a condition marked by penile curvature due to fibrous plaque buildup. The study, sponsored by Uskudar University, has not yet begun enrolling participants but promises to explore innovative treatment pathways for this often-challenging medical condition.
In this article:
- What changed?
- How the trial works
- Frequently Asked Questions
- Conclusion
- Disclaimer
- Announcement details
What changed?
Clinical researchers are preparing for a trial to investigate a non-invasive intervention for Peyronie’s disease—a condition that significantly impacts patients’ quality of life. The study, listed on ClinicalTrials.gov, will evaluate extracorporeal shockwave therapy compared to a control group. The trial’s timeline, participant numbers, and methodology will be key factors once recruitment begins.
How the trial works
Why choose shockwave therapy?
Extracorporeal shockwave therapy is gaining attention in various therapeutic fields due to its ability to mechanically stimulate tissues. Researchers aim to determine whether this approach can benefit patients with Peyronie’s disease by reducing plaque size or improving symptoms like curvature and discomfort during erections.
Who is conducting the trial?
Uskudar University, a Turkish institution known for its involvement in medical research, is the sponsor of this investigation. By examining shockwave therapy’s safety, efficacy, and compliance aspects, researchers will provide actionable data for clinicians and patients alike.
Not yet recruiting
As of January 2026, this trial has not started recruiting patients. Interested parties in the medical device and regulatory sectors should monitor updates on ClinicalTrials.gov (study ID NCT07317297).
Frequently Asked Questions
1. What is Peyronie’s disease?
Peyronie’s disease is a condition where fibrous plaque forms inside the penis, causing curvature, pain, and other symptoms.
2. What is extracorporeal shockwave therapy?
Extracorporeal shockwave therapy uses sound waves to target tissues and stimulate regenerative processes.
3. How can I follow updates on this trial?
Visit ClinicalTrials.gov and search for the study ID NCT07317297.
Conclusion
The upcoming clinical trial represents a step forward in researching innovative treatments for Peyronie’s disease. Shockwave therapy’s non-invasive nature aligns with modern medical device trends, making discoveries here potentially impactful for future therapeutic devices.
Disclaimer
This content is for informational purposes only and is not intended as legal or clinical advice. Always consult a qualified professional regarding regulatory or medical matters.
Announcement details
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07317297?term=medical+device